Amgen ($AMGN) announced Phase 3 trial results showing that combining Imdelltra with Imfinzi reduced the risk of death by 58% in patients with small-cell lung cancer, compared with Imfinzi alone.…
Amgen Inc. (AMGN) 2026 European Society for Medical Oncology (ESMO) Annual Congress October 24, 2026 2:30 PM EDTCompany ParticipantsCasey Capparelli -...
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
From DrEddyClinic.com - Live Blood Cell Darkfield Analyse Blog: Cancer industry total fraud exposed: Nearly all 'scientific' studies fail to be replicated
